The specter of generic rivalry has repeatedly loomed over copyright’s iconic drug, Viagra, raising questions about the outlook of related medicinal ventures. While early times saw substantial returns, the patent expiration has allowed the way for discounted copies, likely reducing earnings and posing a significant risk for stakeholders seeking st